Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 172 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Follow-Up Questions
Qui est le CEO de Voyager Therapeutics Inc ?
Dr. Alfred Sandrock est le President de Voyager Therapeutics Inc, il a rejoint l'entreprise depuis 2022.
Quelle est la performance du prix de l'action VYGR ?
Le prix actuel de VYGR est de $4.16, il a increased de 0.12% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Voyager Therapeutics Inc ?
Voyager Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Voyager Therapeutics Inc ?
La capitalisation boursière actuelle de Voyager Therapeutics Inc est de $231.0M
Est-ce que Voyager Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 11 analystes ont établi des notations d'analystes pour Voyager Therapeutics Inc, y compris 8 achat fort, 9 achat, 1 maintien, 0 vente et 8 vente forte
